Characterization of Acute Myocardial Damage With Spectral Computed Tomography. (CADAMI-SPECTRAL)

Launched by SALAMANCA UNIVERSITY HOSPITAL · Jul 11, 2024

Keywords

ClinConnect Summary

The CADAMI-SPECTRAL clinical trial is studying a new type of imaging called spectral computed tomography (CT) to help diagnose heart conditions in patients who have chest pain and show signs of heart injury. Traditionally, doctors use a procedure called cardiac magnetic resonance imaging (cMRI) to diagnose conditions like myocarditis (inflammation of the heart), stress cardiomyopathy (heart damage from emotional stress), or cases where heart tests show injury without clear blockages in the arteries. This trial aims to see if spectral CT can provide similar or better information in one test, which could lead to quicker and more accurate diagnoses for patients.

To participate in the study, individuals must be at least 18 years old and have been admitted to the hospital for chest pain and signs of heart injury. They should also have a doctor’s recommendation for a cardiac MRI due to suspected heart issues, but tests must show no significant blockages in the arteries. Participants will undergo both spectral CT and cMRI, and their health will be monitored for a year after the tests to see how well the imaging results predict their heart health in the future. This study is ongoing, and researchers hope to learn more about how to better assess and treat patients with these heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 year.
• • Hospital admission due to chest pain and acute myocardial injury.
• • Clinical indication for cardiac MRI (CMR) due to suspected acute myocardial infarction with coronary angiography showing no significant lesions (\<50%) (MINOCA), acute myocarditis, or stress-induced cardiomyopathy.
• • Signed informed consent.
• Exclusion Criteria:
• • Contraindications to undergo cardiac MRI and CT with administration of gadolinium and/or iodine-based contrast, respectively.
• • Pre-existing cardiomyopathy.
• • Pre-existing chronic ischemic heart disease.
• • Invasive coronary angiography showing coronary lesions ≥50%.